<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK481833" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK481833/" /><meta name="ncbi_pagename" content="Bohring-Opitz Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Bohring-Opitz Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Bohring-Opitz Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/02/15" /><meta name="citation_author" content="Bianca Russell" /><meta name="citation_author" content="Wen-Hann Tan" /><meta name="citation_author" content="John M Graham, Jr" /><meta name="citation_pmid" content="29446906" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK481833/" /><meta name="citation_keywords" content="Oberklaid-Danks Syndrome" /><meta name="citation_keywords" content="Oberklaid-Danks Syndrome" /><meta name="citation_keywords" content="Polycomb group protein ASXL1" /><meta name="citation_keywords" content="ASXL1" /><meta name="citation_keywords" content="Bohring-Opitz Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Bohring-Opitz Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Bianca Russell" /><meta name="DC.Contributor" content="Wen-Hann Tan" /><meta name="DC.Contributor" content="John M Graham, Jr" /><meta name="DC.Date" content="2018/02/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK481833/" /><meta name="description" content="Bohring-Opitz syndrome (BOS) is characterized by distinctive facial features and posture, growth failure, variable but usually severe intellectual disability, and variable anomalies. The facial features may include microcephaly or trigonocephaly / prominent (but not fused) metopic ridge, hypotonic facies with full cheeks, synophrys, glabellar and eyelid nevus flammeus (simplex), prominent globes, widely set eyes, palate anomalies, and micrognathia. The BOS posture, which is most striking in early childhood and often becomes less apparent with age, is characterized by flexion at the elbows with ulnar deviation and flexion of the wrists and metacarpophalangeal joints. Feeding difficulties in early childhood, including cyclic vomiting, have a significant impact on overall health; feeding tends to improve with age. Seizures are common and typically responsive to standard epileptic medications. Minor cardiac anomalies and transient bradycardia and apnea may be present. Affected individuals may experience recurrent infections, which also tend to improve with age. Isolated case reports suggest that individuals with BOS are at greater risk for Wilms tumor than the general population, but large-scale epidemiologic studies have not been conducted." /><meta name="og:title" content="Bohring-Opitz Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Bohring-Opitz syndrome (BOS) is characterized by distinctive facial features and posture, growth failure, variable but usually severe intellectual disability, and variable anomalies. The facial features may include microcephaly or trigonocephaly / prominent (but not fused) metopic ridge, hypotonic facies with full cheeks, synophrys, glabellar and eyelid nevus flammeus (simplex), prominent globes, widely set eyes, palate anomalies, and micrognathia. The BOS posture, which is most striking in early childhood and often becomes less apparent with age, is characterized by flexion at the elbows with ulnar deviation and flexion of the wrists and metacarpophalangeal joints. Feeding difficulties in early childhood, including cyclic vomiting, have a significant impact on overall health; feeding tends to improve with age. Seizures are common and typically responsive to standard epileptic medications. Minor cardiac anomalies and transient bradycardia and apnea may be present. Affected individuals may experience recurrent infections, which also tend to improve with age. Isolated case reports suggest that individuals with BOS are at greater risk for Wilms tumor than the general population, but large-scale epidemiologic studies have not been conducted." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK481833/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/bohring-opitz/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK481833/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE895358E040ADB10000000001040072.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK481833_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK481833_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bloom/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bofs/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK481833_"><span class="title" itemprop="name">Bohring-Opitz Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Oberklaid-Danks Syndrome</div><p class="contrib-group"><span itemprop="author">Bianca Russell</span>, MD, <span itemprop="author">Wen-Hann Tan</span>, BMBS, and <span itemprop="author">John M Graham, Jr</span>, MD, ScD.</p><a data-jig="ncbitoggler" href="#__NBK481833_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK481833_ai__"><div class="contrib half_rhythm"><span itemprop="author">Bianca Russell</span>, MD<div class="affiliation small">Cincinnati Children's Hospital<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@llessur.acnaib" class="oemail">gro.cmhcc@llessur.acnaib</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Wen-Hann Tan</span>, BMBS<div class="affiliation small">Boston Children's Hospital<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dravrah.snerdlihc@nat.nnah-new" class="oemail">ude.dravrah.snerdlihc@nat.nnah-new</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John M Graham, Jr</span>, MD, ScD<div class="affiliation small">Cedars Sinai Medical Center Department of Pediatrics<br />Harbor-UCLA Medical Center<br />Emeritus Professor of Pediatrics, David Geffen School of Medicine at UCLA<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.shsc@maharg.nhoj" class="oemail">gro.shsc@maharg.nhoj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 15, 2018</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="bohring-opitz.Summary" itemprop="description"><h2 id="_bohring-opitz_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Bohring-Opitz syndrome (BOS) is characterized by distinctive facial features and posture, growth failure, variable but usually severe intellectual disability, and variable anomalies. The facial features may include microcephaly or trigonocephaly / prominent (but not fused) metopic ridge, hypotonic facies with full cheeks, synophrys, glabellar and eyelid nevus flammeus (simplex), prominent globes, widely set eyes, palate anomalies, and micrognathia. The BOS posture, which is most striking in early childhood and often becomes less apparent with age, is characterized by flexion at the elbows with ulnar deviation and flexion of the wrists and metacarpophalangeal joints. Feeding difficulties in early childhood, including cyclic vomiting, have a significant impact on overall health; feeding tends to improve with age. Seizures are common and typically responsive to standard epileptic medications. Minor cardiac anomalies and transient bradycardia and apnea may be present. Affected individuals may experience recurrent infections, which also tend to improve with age. Isolated case reports suggest that individuals with BOS are at greater risk for Wilms tumor than the general population, but large-scale epidemiologic studies have not been conducted.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Bohring-Opitz syndrome (BOS) is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical features and/or the identification of a constitutional <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ASXL1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations.</i> Cyclic vomiting may be managed by identification and avoidance of triggers, daily maintenance medication, and early abortive treatment; G-tubes or GJ-tubes may decrease aspiration and improve nutrition. Due to the prevalence of obstructive sleep apnea, polysomnography should be considered. Referral to a craniofacial team should be considered for those with palatal abnormalities, micrognathia, or obstructive sleep apnea. Tracheostomy may be considered for those with recurrent aspiration who develop secondary lung disease, or in those with severe sleep apnea that is not adequately treated with noninvasive pressure support (e.g., CPAP, BiPAP) or surgical intervention (e.g., mandibular distraction). Standard management is indicated for seizures, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defects, intellectual disability, myopia, urinary tract infections, urinary retention, and renal stones.</p><p><i>Prevention of primary manifestations.</i> Adequate treatment of severe emesis can decrease hospitalizations, infectious exposures, and ascending aspiration.</p><p><i>Surveillance:</i> Renal ultrasound every three months from birth to age eight to screen for the development of Wilms tumor; frequent monitoring of growth and development; close monitoring of feeding intolerance with a gastroenterology specialist; regular follow up for vision optimization.</p><p><i>Agents/circumstances to avoid.</i> Triggers for vomiting should be avoided and managed with prophylactic antiemetics prior to the exposure.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Bohring-Opitz syndrome (BOS) is typically the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ASXL1</i>. When BOS results from a <i>de novo</i> variant, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is small. No individuals with BOS have been reported to reproduce. Although the vast majority of BOS occurs as the result of a <i>de novo</i> variant in <i>ASXL1</i>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to evaluate a pregnancy at theoretically increased risk as a result of constitutional and/or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for an <i>ASXL1</i> pathogenic variant in a clinically unaffected parent.</p></div></div><div id="bohring-opitz.Diagnosis"><h2 id="_bohring-opitz_Diagnosis_">Diagnosis</h2><p>Prior to the identification of the molecular cause of Bohring-Opitz syndrome (BOS), <a class="bk_pop" href="#bohring-opitz.REF.hastings.2011.513">Hastings et al [2011]</a> had proposed clinical diagnostic criteria for the condition. Ultimately, only five individuals used to develop these clinical diagnostic criteria were molecularly confirmed to have BOS. Therefore, the specificity of these diagnostic criteria is unclear.</p><div id="bohring-opitz.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Bohring-Opitz syndrome <b>should be suspected</b> in individuals with the following clinical features [<a class="bk_pop" href="#bohring-opitz.REF.bohring.1999.438">Bohring et al 1999</a>, <a class="bk_pop" href="#bohring-opitz.REF.bohring.2006.1257">Bohring et al 2006</a>, <a class="bk_pop" href="#bohring-opitz.REF.hastings.2011.513">Hastings et al 2011</a>, <a class="bk_pop" href="#bohring-opitz.REF.magini.2012.917">Magini et al 2012</a>, <a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>].</p><p><b>Craniofacial appearance</b> (<a class="figpopup" href="/books/NBK481833/figure/bohring-opitz.F1/?report=objectonly" target="object" rid-figpopup="figbohringopitzF1" rid-ob="figobbohringopitzF1">Figure 1</a>)</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbohringopitzF1" co-legend-rid="figlgndbohringopitzF1"><a href="/books/NBK481833/figure/bohring-opitz.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figbohringopitzF1" rid-ob="figobbohringopitzF1"><img class="small-thumb" src="/books/NBK481833/bin/bohring-opitz-Image001.gif" src-large="/books/NBK481833/bin/bohring-opitz-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndbohringopitzF1"><h4 id="bohring-opitz.F1"><a href="/books/NBK481833/figure/bohring-opitz.F1/?report=objectonly" target="object" rid-ob="figobbohringopitzF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Facial features of individuals with BOS at varying ages A-B. 2 years</p></div></div><ul><li class="half_rhythm"><div>Microcephaly or trigonocephaly / prominent (but not necessarily fused) metopic ridge</div></li><li class="half_rhythm"><div>Glabellar and eyelid nevus flammeus (simplex) that fades with age</div></li><li class="half_rhythm"><div>Prominent globes</div></li><li class="half_rhythm"><div>Cleft lip</div></li><li class="half_rhythm"><div>Palatal anomalies: cleft palate, high arched palate, or prominent palatine ridges</div></li><li class="half_rhythm"><div>Micrognathia and/or retrognathia</div></li></ul><p><b>Growth and feeding</b></p><ul><li class="half_rhythm"><div>Intrauterine growth restriction</div></li><li class="half_rhythm"><div>Severe feeding difficulties with chronic emesis that typically improves with age</div></li><li class="half_rhythm"><div>Poor postnatal weight gain and linear growth, often exacerbated by severe feeding intolerance</div></li></ul><p><b>Neurologic</b></p><ul><li class="half_rhythm"><div>Developmental delay or intellectual disability in the severe-to-profound range with minimal or complete lack of expressive language</div></li><li class="half_rhythm"><div>Seizures</div></li></ul><p><b>Respiratory.</b> Recurrent infections (commonly respiratory) in early childhood that improve with age</p><p><b>Sleep</b></p><ul><li class="half_rhythm"><div>Sleep disturbance</div></li><li class="half_rhythm"><div>Obstructive sleep apnea</div></li></ul><p><b>Ophthalmologic</b></p><ul><li class="half_rhythm"><div>High myopia presenting in infancy that may worsen over the first years of life</div></li><li class="half_rhythm"><div>Variable optic nerve and retinal anomalies</div></li></ul><p><b>BOS posture</b> (<a class="figpopup" href="/books/NBK481833/figure/bohring-opitz.F2/?report=objectonly" target="object" rid-figpopup="figbohringopitzF2" rid-ob="figobbohringopitzF2">Figure 2</a>)</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbohringopitzF2" co-legend-rid="figlgndbohringopitzF2"><a href="/books/NBK481833/figure/bohring-opitz.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figbohringopitzF2" rid-ob="figobbohringopitzF2"><img class="small-thumb" src="/books/NBK481833/bin/bohring-opitz-Image002.gif" src-large="/books/NBK481833/bin/bohring-opitz-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndbohringopitzF2"><h4 id="bohring-opitz.F2"><a href="/books/NBK481833/figure/bohring-opitz.F2/?report=objectonly" target="object" rid-ob="figobbohringopitzF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Typical BOS posture with flexion at the elbows, ulnar deviation, flexion of the wrists and metacarpophalangeal joints, and hypertonic extremities with central hypotonia From Hastings et al [2011]. Republished with permission.</p></div></div><ul><li class="half_rhythm"><div>Flexion at the elbows with ulnar deviation and flexion of the wrists and metacarpophalangeal joints; most noticeable in early childhood and usually less obvious with age</div></li><li class="half_rhythm"><div>Truncal hypotonia with hypertonia of the extremities</div></li></ul></div><div id="bohring-opitz.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of Bohring-Opitz syndrome <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical features (see <a href="#bohring-opitz.Suggestive_Findings">Suggestive Findings</a>) and/or by identification of a constitutional <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ASXL1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK481833/table/bohring-opitz.T.molecular_genetic_testin/?report=objectonly" target="object" rid-figpopup="figbohringopitzTmoleculargenetictestin" rid-ob="figobbohringopitzTmoleculargenetictestin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, or <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ASXL1</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ASXL1</i> and other genes of interest (see <a href="#bohring-opitz.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>ASXL1</i>) fails to confirm a diagnosis in an individual with features of Bohring-Opitz syndrome. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="bohring-opitz.T.molecular_genetic_testin" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Bohring-Opitz Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK481833/table/bohring-opitz.T.molecular_genetic_testin/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bohring-opitz.T.molecular_genetic_testin_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ASXL1</i></td><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20/24 (83%)&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_bohring-opitz.T.molecular_genetic_testin_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="bohring-opitz.TF.1.1"><p class="no_margin">See <a href="/books/NBK481833/#bohring-opitz.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="bohring-opitz.TF.1.2"><p class="no_margin">See <a href="#bohring-opitz.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="bohring-opitz.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="bohring-opitz.TF.1.4"><p class="no_margin">The denominator represents only those individuals in the literature who have undergone <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>ASXL1</i>; some clinically diagnosed individuals whose information has been published have not undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div></dd><dt>5. </dt><dd><div id="bohring-opitz.TF.1.5"><p class="no_margin">Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for <i>ASXL1</i> variants, including BOS-associated variants, may be found in the elderly or in other non-BOS cohorts (i.e., cohorts of individuals with cancer); such variants may be reported in reference databases, leading to misclassification of potentially pathogenic variants [<a class="bk_pop" href="#bohring-opitz.REF.carlston.2017.517">Carlston et al 2017</a>]. See <a href="#bohring-opitz.Molecular_Genetics">Molecular Genetics</a>.</p></div></dd><dt>6. </dt><dd><div id="bohring-opitz.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="bohring-opitz.TF.1.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>8. </dt><dd><div id="bohring-opitz.TF.1.8"><p class="no_margin">In four individuals with features suggestive of BOS <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ASXL1</i> failed to identify a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#bohring-opitz.REF.brunner.2000.366">Brunner et al 2000</a>, <a class="bk_pop" href="#bohring-opitz.REF.hastings.2010.202">Hastings et al 2010</a>, <a class="bk_pop" href="#bohring-opitz.REF.hastings.2011.513">Hastings et al 2011</a>, <a class="bk_pop" href="#bohring-opitz.REF.hoischen.2011.729">Hoischen et al 2011</a>]. It is unclear if these individuals have a different genetic syndrome with clinical features overlapping those of BOS. <a class="bk_pop" href="#bohring-opitz.REF.greenhalgh.2003.15">Greenhalgh et al [2003]</a> reported two sibs with clinical features of BOS in whom a different diagnosis was subsequently confirmed [<a class="bk_pop" href="#bohring-opitz.REF.bruel.2017.830">Bruel et al 2017</a>].</p></div></dd></dl></div></div></div></div></div><div id="bohring-opitz.Clinical_Characteristics"><h2 id="_bohring-opitz_Clinical_Characteristics_">Clinical Characteristics</h2><div id="bohring-opitz.Clinical_Description"><h3>Clinical Description</h3><p>Bohring-Opitz syndrome (BOS) is a rare condition characterized by distinctive facial features and posture, variable but usually severe intellectual disability, growth failure, and variable anomalies. Feeding difficulties have a significant impact on overall health in early childhood; feeding tends to improve with age. This section summarizes clinical data from numerous case reports and case series; see <a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al [2015]</a> and references therein, <a class="bk_pop" href="#bohring-opitz.REF.dangiolo.2015.3161">Dangiolo et al [2015]</a>, and <a href="#bohring-opitz.Suggested_Reading">Suggested Reading</a>. Additional references are cited where appropriate.</p><p><b>Craniofacial.</b> Individuals with BOS have a characteristic facial appearance (see <a href="#bohring-opitz.Suggestive_Findings">Suggestive Findings</a>), although significant variability is observed. The most striking and consistent features are a prominent glabellar nevus flammeus (simplex) that fades with age, synophrys that becomes more prominent with age, hypotonic facies with full cheeks, and prominent or proptotic eyes. The majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals also have hypertrichosis with rapidly growing hair and nails.</p><p>Other features widely, but variably, reported include cleft lip with or without cleft palate, high arched palate, widely spaced eyes (hypertelorism), depressed and wide nasal bridge, anteverted nares, and low-set ears with increased posterior angulation.</p><p><b>Growth.</b> Mild intrauterine growth restriction has been noted, but many infants are products of healthy pregnancies with average or low-average birth weights. Poor growth is typically noted in the first year of life and is often clinically attributed to chronic emesis and feeding intolerance. Adequate nutrition does play a role in early growth, but even those without feeding intolerance typically display poor long-term growth.</p><p><b>Feeding.</b> Most children have had feeding issues beginning in infancy and generally improving or resolving in early childhood. Historically, feeding issues have been presumed to be secondary to severe gastroesophageal reflux, but initial case reports did not produce diagnostic evidence of gastroesophageal reflux or demonstrate improvement on traditional antireflux therapies. Recent publications have suggested a neurogenic etiology, including cyclic vomiting with possible poor gastric motility, as the underlying cause of the chronic emesis [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>]. Given the frequency of emesis, there is a high risk for aspiration and dehydration, typically resulting in multiple hospitalizations.</p><p><b>Development and behavior.</b> All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported in the literature have severe-to-profound intellectual disability. Few are able to speak, but many have been able to express basic needs using augmentative and alternative communication (AAC) devices as well as gestures with associated basic vocalizations. Individuals with BOS often have a happy and pleasant demeanor [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>]. Typically, they are able to recognize caregivers and have a social, interactive nature. Most are unable to walk independently, but some have had success using walkers and braces in late childhood. Given the recent increase in rate of diagnosis due to <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing, it is expected that affected individuals with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be reported in the future.</p><p><b>Neurologic.</b> Seizures are common in individuals with BOS and are typically responsive to standard antiepileptic medications. Affected individuals have also been described to have truncal hypotonia with hypertonia of the extremities. A wide range of primary brain anomalies have been reported. Corpus callosum defects are the most common and range from hypoplastic to absent. Dandy-Walker malformation, delayed myelination, and enlarged ventricles have also been described.</p><p><b>Cardiovascular.</b> Idiopathic and transient bradycardia as well as apnea were widely reported in the initial literature that predated the identification of the genetic cause of BOS. Cardiovascular deaths associated with bradycardia and apnea account for four (33%) of the 12 deaths published in the literature (although none of those individuals had a molecular confirmation of BOS). Other minor cardiac anomalies including septal defects and cardiac hypertrophy have also been described in a small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><b>Respiratory.</b> In addition to apnea and bradycardia, respiratory infections are common in infancy and account for about 42% of deaths (5/12). When chronic emesis is treated or improves with age, the rate of respiratory infections decreases [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>]. Tracheostomies have been necessary for some (see <a href="#bohring-opitz.Management">Management</a>).</p><p><b>Sleep.</b> Obstructive sleep apnea and sleep disturbances, including difficulty falling asleep and staying asleep, are frequently reported. Affected individuals with micrognathia may also exhibit tongue-based airway obstruction.</p><p><b>Ophthalmologic.</b> Myopia, often severe, is common in individuals with BOS. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals require corrective lenses in infancy. Retinal and optic nerve abnormalities including colobomas, retinal and optic nerve atrophy, and abnormal coloration of the retinas are also frequently reported.</p><p><b>Immunologic.</b> Recurrent infections may be frequent in early life, although immunodeficiency has not been reported in the literature. The frequency of infections typically declines with age.</p><p><b>Urologic.</b> Urinary retention and recurrent urinary tract infections have been reported in individuals with BOS [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>]. There also appears to be an increased risk for renal stones [Author, personal observation].</p><p><b>Skeletal.</b> The typical BOS posture (see <a href="#bohring-opitz.Suggestive_Findings">Suggestive Findings</a>) is most notable in early childhood and usually becomes less obvious with age. Congenital contractures, dislocations, and pectus excavatum have also been reported.</p><p><b>Malignancy.</b>
Isolated case reports suggest that children with BOS are at greater risk for Wilms tumor than the general population; large-scale epidemiologic studies have not been conducted due to the limited number of individuals diagnosed with BOS. Of three individuals with a clinical diagnosis of BOS and renal neoplasia, two had documented pathogenic variants in <i>ASXL1</i> and bilateral Wilms tumor; Wilms tumor was diagnosed in one at age two years and in the other at age six years [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>]. Another individual with BOS had nephroblastomatosis on autopsy at age five months. This infant later underwent <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ASXL1</i>; no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified [<a class="bk_pop" href="#bohring-opitz.REF.brunner.2000.366">Brunner et al 2000</a>, <a class="bk_pop" href="#bohring-opitz.REF.hoischen.2011.729">Hoischen et al 2011</a>]. Overall, Wilms tumor appears to affect about 7% of individuals with BOS. This risk estimate is based on a very small number of reported cases and thus is likely to change over time as larger cohorts of children and adults with BOS are investigated.</p><p>The only other neoplastic process reported was medulloblastoma in a child age five years with clinical features of BOS in whom a pathogenic <i>ASXL1</i> variant was not identified [<a class="bk_pop" href="#bohring-opitz.REF.hastings.2010.202">Hastings et al 2010</a>, <a class="bk_pop" href="#bohring-opitz.REF.hoischen.2011.729">Hoischen et al 2011</a>].</p><p><b>Other</b></p><ul><li class="half_rhythm"><div>Annular pancreas has been described in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li><li class="half_rhythm"><div>Gallstones have been reported in several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [Author, personal observation].</div></li><li class="half_rhythm"><div>Historically, this condition had been associated with high infant mortality (27% based on data published before 2015), but the current survival rate is likely to be much better due to advances in pediatric care and more aggressive interventions [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>].</div></li></ul></div><div id="bohring-opitz.GenotypePhenotype_Correlat"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been reported to date, but the total number of individuals in whom <i>ASXL1</i> pathogenic variants have been identified is limited.</p></div><div id="bohring-opitz.Nomenclature"><h3>Nomenclature</h3><p>BOS is occasionally known as Oberklaid-Danks syndrome after F Oberklaid and DM Danks, who described one of the early cases of BOS [<a class="bk_pop" href="#bohring-opitz.REF.oberklaid.1975.1348">Oberklaid &#x00026; Danks 1975</a>]. BOS is the more commonly used term.</p></div><div id="bohring-opitz.Prevalence"><h3>Prevalence</h3><p>The prevalence of BOS is unknown; out of 46 clinically diagnosed individuals reported in the literature, 20 had the diagnosis molecularly confirmed.</p><p>Note: Not all clinically diagnosed individuals reported in the literature have undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>ASXL1</i>.</p></div></div><div id="bohring-opitz.Genetically_Related_Alleli"><h2 id="_bohring-opitz_Genetically_Related_Alleli_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>ASXL1</i>.</p><p>Sporadic malignancies (including myelodysplastic syndrome) occurring in the absence of any other findings of Bohring-Opitz syndrome frequently harbor somatic variants in <i>ASXL1</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable. For more details see <a href="#bohring-opitz.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div><div id="bohring-opitz.Differential_Diagnosis"><h2 id="_bohring-opitz_Differential_Diagnosis_">Differential Diagnosis</h2><div id="bohring-opitz.T.disorders_to_consider_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Bohring-Opitz Syndrome (BOS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK481833/table/bohring-opitz.T.disorders_to_consider_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bohring-opitz.T.disorders_to_consider_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of the Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4" id="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/BOS</th><th headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4" id="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from BOS</th></tr></thead><tbody><tr><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C syndrome (Opitz trigonocephaly syndrome)&#x000a0;<sup>1</sup><br />(OMIM <a href="http://omim.org/entry/211750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">211750</a>)</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CD96</i></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Severe DD/ID</div></li><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>Trigonocephaly</div></li><li class="half_rhythm"><div>Upslanting palpebral fissures</div></li><li class="half_rhythm"><div>Retrognathia</div></li><li class="half_rhythm"><div>Low-set ears</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in BOS, not in C syndrome:
<ul><li class="half_rhythm"><div>Nevus flammeus (simplex) over glabella</div></li><li class="half_rhythm"><div>BOS posture</div></li><li class="half_rhythm"><div>Poor linear growth</div></li><li class="half_rhythm"><div>Feeding difficulties</div></li><li class="half_rhythm"><div>High myopia</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Shashi-Pena syndrome (<i>ASXL2</i> syndrome)&#x000a0;<sup>2</sup><br />(OMIM <a href="http://omim.org/entry/617190" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617190</a>)</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ASXL2</i></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>DD</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Feeding difficulties in infancy</div></li><li class="half_rhythm"><div>Nevus flammeus (simplex) over the glabella</div></li><li class="half_rhythm"><div>Facial characteristics (particularly widely spaced eyes, prominent globes, &#x00026; low-set or posteriorly rotated ears)</div></li><li class="half_rhythm"><div>Hypertrichosis (2 of 6 reported cases)</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in BOS:
<ul><li class="half_rhythm"><div>Severe to profound ID</div></li><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>BOS posture</div></li></ul>
Common in Shashi-Pena syndrome:
<ul><li class="half_rhythm"><div>Variable ID (borderline to severe)</div></li><li class="half_rhythm"><div>Macrocephaly</div></li><li class="half_rhythm"><div>Lesser feeding difficulties &#x00026; normal weight gain</div></li><li class="half_rhythm"><div>Episodic hypoglycemia of unknown etiology</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bainbridge-Ropers syndrome (<i>ASXL3</i> syndrome)&#x000a0;<sup>3</sup><br />(OMIM <a href="http://omim.org/entry/615485" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615485</a>)</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ASXL3</i></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Severe DD/ID w/minimal speech</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Feeding difficulties</div></li><li class="half_rhythm"><div>Poor linear growth &#x00026; weight gain</div></li><li class="half_rhythm"><div>Microcephaly</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in BOS; not typical in Bainbridge-Ropers syndrome:
<ul><li class="half_rhythm"><div>IUGR</div></li><li class="half_rhythm"><div>Nevus flammeus (simplex) over the glabella</div></li><li class="half_rhythm"><div>Prominent globes</div></li><li class="half_rhythm"><div>Typical BOS posture</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cdls/">Cornelia de Lange syndrome</a><br />(CdLS)</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HDAC8</i><br /><i>NIPBL</i><br /><i>RAD21</i><br /><i>SMC1A</i><br /><i>SMC3</i></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />XL&#x000a0;<sup>4</sup></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>DD/ID</div></li><li class="half_rhythm"><div>Prenatal and postnatal growth restriction</div></li><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>Hypertrichosis</div></li><li class="half_rhythm"><div>Small feet</div></li><li class="half_rhythm"><div>In <i>HDAC8</i>-related CdLS, nevus flammeus (simplex) over the glabella &#x00026; widely spaced eyes&#x000a0;<sup>5</sup></div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in BOS:
<ul><li class="half_rhythm"><div>More severe feeding intolerance</div></li><li class="half_rhythm"><div>High myopia</div></li><li class="half_rhythm"><div>BOS posture</div></li><li class="half_rhythm"><div>Prominent globes</div></li></ul>
Common in CdLS:
<ul><li class="half_rhythm"><div>Small hands &#x00026; feet sometimes w/upper-limb reduction defects</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KLHL7</i>-associated syndrome&#x000a0;<sup>6</sup></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KLHL7</i></td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>DD/ID</div></li><li class="half_rhythm"><div>Feeding difficulties</div></li><li class="half_rhythm"><div>IUGR</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>Hypoplastic corpus callosum</div></li><li class="half_rhythm"><div>Facial characteristics: prominent eyes, anteverted nares</div></li><li class="half_rhythm"><div>Facial nevus flammeus (simplex)</div></li><li class="half_rhythm"><div>Hypertrichosis</div></li><li class="half_rhythm"><div>Joint contractures</div></li><li class="half_rhythm"><div>BOS posture</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_1_4 hd_h_bohring-opitz.T.disorders_to_consider_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In <i>KLHL7</i>-associated syndrome:
<ul><li class="half_rhythm"><div>Absence of high myopia &#x00026; retinal/optic nerve atrophy</div></li><li class="half_rhythm"><div>Retinitis pigmentosa in childhood</div></li><li class="half_rhythm"><div>Hyperthermia</div></li><li class="half_rhythm"><div>Oropharyngeal muscle contraction</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; DD/ID = developmental delay / intellectual disability; IUGR = intrauterine growth restriction; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="bohring-opitz.TF.2.1"><p class="no_margin">The phenotypic spectrum of C syndrome is not well defined, apart from the reportedly more common features. The <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> is also unclear since the molecular etiology remains elusive. A Japanese individual with a clinical diagnosis of C syndrome had a chromosomal <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> that disrupted <i>CD96</i> (also known as <i>TACTILE</i>), and another Japanese individual with a clinical diagnosis of C syndrome had a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <i>CD96</i> [<a class="bk_pop" href="#bohring-opitz.REF.kaname.2007.835">Kaname et al 2007</a>]. However, these findings have not been replicated since 2007, so it remains unclear whether pathogenic variants in <i>CD96</i> could result in C syndrome. More recently, <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants in <i>IFT140</i> were found in an individual with a clinical diagnosis of C syndrome &#x02013; along with clinical features suggestive of a ciliopathy, which had not been previously reported in C syndrome [<a class="bk_pop" href="#bohring-opitz.REF.pe_apadilla.2017.640">Pe&#x000f1;a-Padilla et al 2017</a>]. Thus, it is unclear whether this is distinct from "classic" C syndrome.</p></div></dd><dt>2. </dt><dd><div id="bohring-opitz.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#bohring-opitz.REF.shashi.2016.991">Shashi et al [2016]</a></p></div></dd><dt>3. </dt><dd><div id="bohring-opitz.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#bohring-opitz.REF.balasubramanian.2017.537">Balasubramanian et al [2017]</a>, <a class="bk_pop" href="#bohring-opitz.REF.kuechler.2017.183">Kuechler et al [2017]</a></p></div></dd><dt>4. </dt><dd><div id="bohring-opitz.TF.2.4"><p class="no_margin"><i>NIPBL</i>-, <i>RAD21</i>-, and <i>SMC3</i>-related CdLS are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; <i>HDAC8</i>- and <i>SMC1A</i>-related CdLS are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div></dd><dt>5. </dt><dd><div id="bohring-opitz.TF.2.5"><p class="no_margin">Pathogenic variants in <i>HDAC8</i> result in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> subtype of CdLS that is more severe in males and bears facial resemblance to BOS, with features not typically seen in "classic" CdLS: nevus flammeus (simplex) over the glabella and widely spaced eyes [<a class="bk_pop" href="#bohring-opitz.REF.kaiser.2014.2888">Kaiser et al 2014</a>, <a class="bk_pop" href="#bohring-opitz.REF.parenti.2016.564">Parenti et al 2016</a>].</p></div></dd><dt>6. </dt><dd><div id="bohring-opitz.TF.2.6"><p class="no_margin"><a class="bk_pop" href="#bohring-opitz.REF.angius.2016.236">Angius et al [2016]</a>, <a class="bk_pop" href="#bohring-opitz.REF.bruel.2017.830">Bruel et al [2017]</a></p></div></dd></dl></div></div></div></div><div id="bohring-opitz.Management"><h2 id="_bohring-opitz_Management_">Management</h2><div id="bohring-opitz.Evaluations_Following_Init"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the spectrum of manifestations and medical needs in an individual diagnosed with Bohring-Opitz syndrome (BOS), the following evaluations are recommended if they have not already been completed.</p><div id="bohring-opitz.T.recommended_evaluations" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis of Bohring-Opitz Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK481833/table/bohring-opitz.T.recommended_evaluations/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bohring-opitz.T.recommended_evaluations_lrgtbl__"><table><thead><tr><th id="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">System/Concern</th><th id="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evaluation</th><th id="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Growth</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Weight, length/height, &#x00026; head circumference measurements plotted on standard growth chart</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Goal: normal weight-for-length or body mass index</div></li><li class="half_rhythm"><div>Expected final adult height: &#x0003c;2nd centile</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>ENT/Mouth</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Craniofacial evaluation if cleft lip/palate, micrognathia, or obstructive sleep apnea is present</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If mainly due to tongue-based airway obstruction, severe obstructive sleep apnea may be treatable by adenoidectomy or mandibular distraction.</td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Feeding evaluation (w/consideration of swallowing study) to assess for chronic emesis &#x00026; aspiration risk</div></li><li class="half_rhythm"><div>Consideration of gastric emptying time to assess for poor gastric motility</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment for signs/symptoms of seizures</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If present, consider neurology evaluation &#x00026; head MRI.</td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Evaluation by developmental specialists incl speech, occupational, &#x00026; physical therapists</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram for cardiac anatomy</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment for apnea/bradycardia (more common in younger individuals)</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider sleep study if sleep apnea is a concern.</td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmology evaluation</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For high myopia &#x00026; retinal/optic nerve defects</td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Genitourinary</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline renal ultrasound</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess renal structure &#x00026; screen for Wilms tumor</td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedic evaluation if bony anomalies noted</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_bohring-opitz.T.recommended_evaluations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="bohring-opitz.Treatment_of_Manifestation"><h3>Treatment of Manifestations</h3><div id="bohring-opitz.T.treatment_of_manifestati" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with BOS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK481833/table/bohring-opitz.T.treatment_of_manifestati/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bohring-opitz.T.treatment_of_manifestati_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Manifestation/Concern</th><th id="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th><th id="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Poor growth &#x00026; feeding due to chronic severe emesis&#x000a0;<sup>1</sup></b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>For cyclic vomiting: identification &#x00026; avoidance of triggers,&#x000a0;<sup>2</sup> daily maintenance medication,&#x000a0;<sup>3</sup> &#x00026; early abortive treatment at episode onset&#x000a0;<sup>4</sup></div></li><li class="half_rhythm"><div>G-tubes or GJ-tubes often decrease aspiration &#x00026; improve nutrition;&#x000a0;<sup>5</sup> consider thickened feeds.</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fundoplication &#x00026; traditional antireflux management w/acid blockers are typically not beneficial if gastroesophageal reflux is not the underlying etiology.</td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cleft lip &#x00026;/or palate</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Primary closure of cleft lip along standard timeline</div></li><li class="half_rhythm"><div>Consider leaving cleft palates unrepaired when speech is lacking.</div></li><li class="half_rhythm"><div>Palate repair in a child at risk for obstructive apnea may &#x02191; risk.</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Assess language &#x00026; mobility to determine plan for palate closure &#x00026; alveolar bone grafting.</div></li><li class="half_rhythm"><div>Palate repair may be warranted in individuals w/language skills.</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Frequent infections &#x00026;/or aspiration pneumonia&#x000a0;<sup>4</sup></b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Aggressive management of chronic emesis</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Fever or increase in emesis</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Urinalysis &#x00026; urine culture for possible urinary tract infection</div></li><li class="half_rhythm"><div>Evaluation for other possible sources of infection, pain, or exposure</div></li></ul>
</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard antiepileptic medications</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most individuals respond to monotherapy.</td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Congenital heart defects</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard management</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b><br /><b>symptoms</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tracheostomy may be effective in:
<ul><li class="half_rhythm"><div>Creating a safe airway</div></li><li class="half_rhythm"><div>Treating aspiration &#x02192; lung disease</div></li><li class="half_rhythm"><div>Treating severe obstructive sleep apnea not controlled by noninvasive pressure support (e.g., CPAP, BiPAP) or surgical management (e.g., adenoidectomy, mandibular distraction)</div></li></ul>
Aspiration may also be amenable to treatment w/postpyloric feedings (e.g., by gastrojejunostomy).</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Inhaled albuterol &#x00026; inhaled steroids have improved respiratory status in some, although typical findings for reactive airway disease were lacking [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>].</div></li><li class="half_rhythm"><div>Descending aspiration of saliva can often be managed w/glycopyrrolate or salivary Botox injections.</div></li></ul>
</td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sleep disturbances</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Melatonin, treatment of anemia</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Myopia</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Corrective lenses, often first prescribed in infancy</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Urinary retention, urinary tract infections, renal stones</b></td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatments</td><td headers="hd_h_bohring-opitz.T.treatment_of_manifestati_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Appropriate management of these conditions can improve emesis &#x00026; hospitalization rate.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="bohring-opitz.TF.4.1"><p class="no_margin">If vomiting is well controlled, growth typically improves, hospitalizations for dehydration and aspiration decrease, and overall health and well-being improve, although the rate of linear growth and weight gain remains poor. Lifelong feeding interventions may not be required, so periodic reexamination is appropriate.</p></div></dd><dt>2. </dt><dd><div id="bohring-opitz.TF.4.2"><p class="no_margin">Triggers such as vaccines, infections, and anesthesia have been reported, although this is not a reason to avoid vaccination and anesthesia: all children with BOS should receive the full course of standard vaccinations as recommended by the local authorities.</p></div></dd><dt>3. </dt><dd><div id="bohring-opitz.TF.4.3"><p class="no_margin">Cyproheptadine has been used for daily maintenance therapy.</p></div></dd><dt>4. </dt><dd><div id="bohring-opitz.TF.4.4"><p class="no_margin">Prophylactic treatment prior to a trigger exposure with antiemetics has been beneficial. Abortive treatment includes lorazepam, ondansetron, and acetaminophen or some combination of an antiemetic, pain reliever, and sedative.</p></div></dd><dt>5. </dt><dd><div id="bohring-opitz.TF.4.5"><p class="no_margin">Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with feeding difficulties require a permanent feeding tube (G-tube or GJ-tube). Thickened feeds can help with emesis, and while G-tubes often do not stop emesis completely, they can limit the amount of nutrition lost through vomiting.</p></div></dd></dl></div></div></div><div id="bohring-opitz.Developmental_Delay__Intel"><h4>Developmental Delay / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed.</p><p><b>Ages 5-21 years.</b> In the US, an IEP based on the individual's level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district until age 21.</p><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life.</p><p>Consideration of private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs is recommended. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p><p>In the US:</p><ul><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div><div id="bohring-opitz.Motor_Dysfunction"><h4>Motor Dysfunction</h4><p><b>Gross motor dysfunction</b></p><ul><li class="half_rhythm"><div>Physical therapy is recommended to maximize mobility.</div></li><li class="half_rhythm"><div>Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</div></li></ul><p><b>Fine motor dysfunction.</b> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.</p><p><b>Oral motor dysfunction.</b> Assuming that the individual is safe to eat by mouth, feeding therapy &#x02013; typically from an occupational or speech therapist &#x02013; is recommended for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who have difficulty feeding due to poor oral motor control.</p><p><b>Communication issues.</b> Consider evaluation for alternative means of communication (e.g., <a href="http://www.asha.org/NJC/AAC/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Augmentative and Alternative Communication</a> [AAC] for individuals who have expressive language difficulties.</p></div></div><div id="bohring-opitz.Prevention_of_Primary_Mani"><h3>Prevention of Primary Manifestations</h3><p>Adequate treatment of severe emesis can decrease hospitalizations, infectious exposures, and aspiration.</p></div><div id="bohring-opitz.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Renal ultrasound every three months from birth to age eight years to screen for the development of Wilms tumor [<a class="bk_pop" href="#bohring-opitz.REF.russell.2015.2122">Russell et al 2015</a>]</div></li><li class="half_rhythm"><div>Frequent monitoring of growth and development with interventions as needed (see <a href="#bohring-opitz.Treatment_of_Manifestation">Treatment of Manifestations</a>)</div></li><li class="half_rhythm"><div>Close management of feeding intolerance with a gastroenterology specialist</div></li><li class="half_rhythm"><div>Regular follow up with an ophthalmologist for vision optimization</div></li></ul></div><div id="bohring-opitz.AgentsCircumstances_to_Avo"><h3>Agents/Circumstances to Avoid</h3><p>Triggers for vomiting should be avoided and managed with prophylactic antiemetics prior to the exposure (see <a href="#bohring-opitz.Treatment_of_Manifestation">Treatment of Manifestations</a>).</p></div><div id="bohring-opitz.Evaluation_of_Relatives_at"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#bohring-opitz.Related_Genetic_Counseling">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="bohring-opitz.Therapies_Under_Investigat"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="bohring-opitz.Genetic_Counseling"><h2 id="_bohring-opitz_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="bohring-opitz.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Bohring-Opitz syndrome (BOS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p>Note: A previously published sib pair identified as having BOS (which could have implied either <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent) have subsequently been identified as having another genetic condition [<a class="bk_pop" href="#bohring-opitz.REF.greenhalgh.2003.15">Greenhalgh et al 2003</a>, <a class="bk_pop" href="#bohring-opitz.REF.bruel.2017.830">Bruel et al 2017</a>].</p></div><div id="bohring-opitz.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most probands with BOS reported to date have the disorder as a result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>ASXL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>ASXL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date have had a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>ASXL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, suggesting a low risk to sibs.</div></li><li class="half_rhythm"><div>If the <i>ASXL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#bohring-opitz.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with BOS are not known to reproduce.</p><p><b>Other family members.</b> Given that most probands with BOS reported to date have the disorder as a result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>ASXL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to other family members is presumed to be low.</p></div><div id="bohring-opitz.Related_Genetic_Counseling"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to parents of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="bohring-opitz.Prenatal_Testing_and_Preim"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ASXL1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="bohring-opitz.Resources"><h2 id="_bohring-opitz_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Bohring-Opitz Syndrome Family Support Group</b></div><div><b>Phone:</b> +31 (0) 23 531 31 96; (+44)7809 289014; 626-429-8446</div><div><b>Email:</b> sunne@bohring-opitz.org; anniebee104@yahoo.co.uk; sheri@bohring-opitz.org</div><div><a href="http://www.bohring-opitz.org/parental-support" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.bohring-opitz.org</a></div></li><li class="half_rhythm"><div><b>Bohring-Opitz Syndrome Foundation</b></div><div>P.O. Box 560475</div><div>Orlando FL 32856</div><div><b>Email:</b> info@bos-foundation.org</div><div><a href="http://bos-foundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.bos-foundation.org</a></div></li><li class="half_rhythm"><div><b>Clinical Registry for Bohring-Opitz Syndrome and Other ASXL-Related Phenotypes</b></div><div>Supported and co-managed by the BOS Foundation</div><div><b>Phone:</b> 513-636-4760; 617-355-6394</div></li></ul></div><div id="bohring-opitz.Molecular_Genetics"><h2 id="_bohring-opitz_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="bohring-opitz.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Bohring-Optiz Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK481833/table/bohring-opitz.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bohring-opitz.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_bohring-opitz.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_bohring-opitz.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_bohring-opitz.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_bohring-opitz.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_bohring-opitz.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_bohring-opitz.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_bohring-opitz.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/171023" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ASXL1</i></a></td><td headers="hd_b_bohring-opitz.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=171023" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">20q11<wbr style="display:inline-block"></wbr>​.21</a></td><td headers="hd_b_bohring-opitz.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8IXJ9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Polycomb group protein ASXL1</a></td><td headers="hd_b_bohring-opitz.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/ASXL1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ASXL1 @ LOVD</a></td><td headers="hd_b_bohring-opitz.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ASXL1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ASXL1</a></td><td headers="hd_b_bohring-opitz.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ASXL1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ASXL1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="bohring-opitz.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="bohring-opitz.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Bohring-Optiz Syndrome (<a href="/omim/605039,612990" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK481833/table/bohring-opitz.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bohring-opitz.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605039" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605039</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BOHRING-OPITZ SYNDROME; BOPS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612990" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612990</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ADDITIONAL SEX COMBS-LIKE 1; ASXL1</td></tr></tbody></table></div></div><div id="bohring-opitz.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>ASXL1</i> is one of the human orthologs of the additional sex combs <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (Asx), which is an atypical polycomb group (PcG) protein that in <i>Drosophila</i> regulates gene expression by binding to chromatin and by regulating ubiquitination of specific histones (e.g., histone H2A) through activation of specific deubiquitinases. In humans, <i>ASXL1</i>, <i>ASXL2</i>, and <i>ASXL3</i> (<a class="figpopup" href="/books/NBK481833/table/bohring-opitz.T.disorders_to_consider_in/?report=objectonly" target="object" rid-figpopup="figbohringopitzTdisorderstoconsiderin" rid-ob="figobbohringopitzTdisorderstoconsiderin">Table 2</a>) code for putative PcG proteins (for <i>ASXL1</i> see <a href="http://www.uniprot.org/uniprot/Q8IXJ9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.uniprot.org/uniprot/Q8IXJ9</a>) that regulate transcription through various mechanisms, including recruitment of histone H3 in specific cell types and deubiquitination of specific histone H2A. See <a class="bk_pop" href="#bohring-opitz.REF.russell.2013.16">Russell &#x00026; Graham [2013]</a> and references therein for insights into conditions associated with members of the ASXL family.</p><p><b>Gene structure.</b>
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_015338" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015338</a> is the longest <i>ASXL1</i> transcript variant; it is composed of 13 exons. Alternatively spliced transcripts have been reported. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK481833/#bohring-opitz.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> In one report, <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> pathogenic variants were detected in 50% of individuals who had features consistent with a diagnosis of BOS [<a class="bk_pop" href="#bohring-opitz.REF.dangiolo.2015.3161">Dangiolo et al 2015</a>]. See <a href="/books/NBK481833/#bohring-opitz.molgen.TA">Table A</a>, <b>LSDB</b> and <b>HGMD</b>.</p><p>NOTE: <i>ASXL1</i> variants, including BOS-associated variants, have been identified in the elderly or in cohorts of individuals with cancer; such variants can be found in reference population databases. However, these variants are thought to result from hematopoiectic <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> as opposed to BOS-associated <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants [<a class="bk_pop" href="#bohring-opitz.REF.carlston.2017.517">Carlston et al 2017</a> and references therein]. Failure to consider somatic mosaicism may lead to the misclassification of potentially pathogenic variants. See <a href="#bohring-opitz.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_015338" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015338</a> encodes the protein isoform <a href="https://www.ncbi.nlm.nih.gov/protein/NP_056153" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_056153</a> (isoform 1) with 1,541 amino acid residues known as putative polycomb group protein ASXL1.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> frameshift and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> <i>ASXL1</i> pathogenic variants suggest a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism as a cause of BOS [<a href="http://omim.org/entry/605039?search=605039&#x00026;highlight=605039#6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hoischen et al 2011</a>, <a class="bk_pop" href="#bohring-opitz.REF.dangiolo.2015.3161">Dangiolo et al 2015</a>].</p></div><div id="bohring-opitz.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p>Sporadic malignancies (including myelodysplastic syndrome) occurring in the absence of any other findings of BOS frequently harbor somatic variants in <i>ASXL1</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable.</p><p>Somatic <i>ASXL1</i> pathogenic variants are known to be associated with a worse prognosis in persons with myeloid leukemia [<a class="bk_pop" href="#bohring-opitz.REF.abdelwahab.2012.180">Abdel-Wahab et al 2012</a>]. Mice with somatic pathogenic <i>Asxl</i> variants are at high risk for myelodysplastic conditions [<a class="bk_pop" href="#bohring-opitz.REF.abdelwahab.2013.2641">Abdel-Wahab et al 2013</a>], but constitutive <i>Asxl1</i> loss does not produce long-term cell line dysfunction [<a class="bk_pop" href="#bohring-opitz.REF.fisher.2010a.9">Fisher et al 2010a</a>, <a class="bk_pop" href="#bohring-opitz.REF.fisher.2010b.38">Fisher et al 2010b</a>]. Leukemias have not been reported in individuals with <i>ASXL1</i>-related BOS.</p></div></div><div id="bohring-opitz.References"><h2 id="_bohring-opitz_References_">References</h2><div id="bohring-opitz.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.abdelwahab.2012.180">Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. <span><span class="ref-journal">Cancer Cell. </span>2012;<span class="ref-vol">22</span>:180–93.</span> [<a href="/pmc/articles/PMC3422511/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3422511</span></a>] [<a href="/pubmed/22897849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22897849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.abdelwahab.2013.2641">Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. <span><span class="ref-journal">J Exp Med. </span>2013;<span class="ref-vol">210</span>:2641–59.</span> [<a href="/pmc/articles/PMC3832937/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3832937</span></a>] [<a href="/pubmed/24218140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24218140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.angius.2016.236">Angius A, Uva P, Buers I, Oppo M, Puddu A, Onano S, Persico I, Loi A, Marcia L, H&#x000f6;hne W, Cuccuru G, Fotia G, Deiana M, Marongiu M, Atalay HT, Inan S, El Assy O, Smit LM, Okur I, Boduroglu K, Utine GE, K&#x00131;l&#x00131;&#x000e7; E, Zampino G, Crisponi G, Crisponi L, Rutsch F. Bi-allelic mutations in KLHL7 cause a Crisponi/CISS1-like phenotype associated with early-onset retinitis pigmentosa. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">99</span>:236–45.</span> [<a href="/pmc/articles/PMC5005468/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5005468</span></a>] [<a href="/pubmed/27392078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27392078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.balasubramanian.2017.537">Balasubramanian M, Willoughby J, Fry AE, Weber A, Firth HV, Deshpande C, Berg JN, Chandler K, Metcalfe KA, Lam W, Pilz D, Tomkins S. Delineating the phenotypic spectrum of Bainbridge-Ropers syndrome: 12 new patients with de novo, heterozygous, loss-of-function mutations in ASXL3 and review of published literature. <span><span class="ref-journal">J Med Genet. </span>2017;<span class="ref-vol">54</span>:537–43.</span> [<a href="/pubmed/28100473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28100473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.bohring.2006.1257">Bohring A, Oudesluijs GG, Grange DK, Zampino G, Thierry P. New cases of Bohring-Opitz syndrome, update, and critical review of the literature. <span><span class="ref-journal">Am J Med Genet Part A. </span>2006;<span class="ref-vol">140</span>:1257–63.</span> [<a href="/pubmed/16691589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16691589</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.bohring.1999.438">Bohring A, Silengo M, Lerone M, Superneau DW, Spaich C, Braddock SR, Poss A, Opitz JM. Severe end of Opitz trigonocephaly (C) syndrome or new syndrome? <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">85</span>:438–46.</span> [<a href="/pubmed/10405439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10405439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.bruel.2017.830">Bruel AL, Bigoni S, Kennedy J, Whiteford M, Buxton C, Parmeggiani G, Wherlock M, Woodward G, Greenslade M, Williams M, St-Onge J, Ferlini A, Garani G, Ballardini E, van Bon B, Acuna-Hidalgo R, Bohring A, Deleuze J, Boland A, Meyer V, Olaso R, Ginglinger E, Study D, Rivi&#x000e8;re J, Brunner HG, Hoischen A, Newbury-Ecob R, Faivre L, Thauvin-Robinet C, Thevenon J. Expanding the clinical spectrum of recessive truncating mutations of KLHL7 to a Bohring-Opitz-like phenotype. <span><span class="ref-journal">J Med Genet. </span>2017;<span class="ref-vol">54</span>:830–5.</span> [<a href="/pubmed/29074562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29074562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.brunner.2000.366">Brunner HG, Van Tintelen JP, De Boer RJ. Bohring syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">92</span>:366–8.</span> [<a href="/pubmed/10861670" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10861670</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.carlston.2017.517">Carlston CM, O'Donnell-Luria AH, Underhill HR, Cummings BB, Weisburd B, Minikel EV, Birnbaum DP, Tvrdik T, MacArthur DG, Mao R, et al.  Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz syndrome. <span><span class="ref-journal">Hum Mutat. </span>2017;<span class="ref-vol">38</span>:517–23.</span> [<a href="/pmc/articles/PMC5487276/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5487276</span></a>] [<a href="/pubmed/28229513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28229513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.dangiolo.2015.3161">Dangiolo SB, Wilson A, Jobanputra V, Anyane-Yeboa K. Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: review of the most prevalent molecular and phenotypic features of the syndrome. <span><span class="ref-journal">Am J Med Genet Part A. </span>2015;<span class="ref-vol">167A</span>:3161–6.</span> [<a href="/pubmed/26364555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26364555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.fisher.2010a.9">Fisher CL, Lee I, Bloyer S, Bozza S, Chevalier J, Dahl A, Bodner C, Helgason CD, Hess JL, Humphries RK, Brock HW. Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. <span><span class="ref-journal">Dev Biol. </span>2010a;<span class="ref-vol">337</span>:9–15.</span> [<a href="/pmc/articles/PMC2807749/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2807749</span></a>] [<a href="/pubmed/19833123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19833123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.fisher.2010b.38">Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW. Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. <span><span class="ref-journal">Blood. </span>2010b;<span class="ref-vol">115</span>:38–46.</span> [<a href="/pmc/articles/PMC2803690/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2803690</span></a>] [<a href="/pubmed/19861679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19861679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.greenhalgh.2003.15">Greenhalgh KL, Newbury-Ecob RA, Lunt PW, Dolling CL, Hargreaves H, Smithson SF. Siblings with Bohring-Opitz syndrome. <span><span class="ref-journal">Clin Dysmorphol. </span>2003;<span class="ref-vol">12</span>:15–9.</span> [<a href="/pubmed/12514360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12514360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.hastings.2011.513">Hastings R, Cobben JM, Gillessen-Kaesbach G, Goodship J, Hove H, Kjaergaard S, Kemp H, Kingston H, Lunt P, Mansour S, McGowan R, Metcalfe K, Murdoch-Davis C, Ray M, Rio M, Smithson S, Tolmie J, Turnpenny P, van Bon B, Wieczorek D, Newbury-Ecob R. Bohring-Opitz (Oberklaid-Danks) syndrome: clinical study, review of the literature, and discussion of possible pathogenesis. <span><span class="ref-journal">Eur J Hum Genet. </span>2011;<span class="ref-vol">19</span>:513–9.</span> [<a href="/pmc/articles/PMC3083618/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3083618</span></a>] [<a href="/pubmed/21368916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21368916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.hastings.2010.202">Hastings RW, Newbury-Ecob R, Lunt PW. A case of probable Bohring-Opitz syndrome with medulloblastoma. <span><span class="ref-journal">Clin Dysmorphol. </span>2010;<span class="ref-vol">19</span>:202–5.</span> [<a href="/pubmed/20717007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20717007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.hoischen.2011.729">Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wieczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BBBA. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:729–31.</span> [<a href="/pubmed/21706002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21706002</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.kaiser.2014.2888">Kaiser FJ, Ansari M, Braunholz D, Concepci&#x000f3;n Gil-Rodr&#x000ed;guez M, Decroos C, Wilde JJ, Fincher CT, Kaur M, Bando M, Amor DJ, Atwal PS, Bahlo M, Bowman CM, Bradley JJ, Brunner HG, Clark D, Del Campo M, Di Donato N, Diakumis P, Dubbs H, Dyment DA, Eckhold J, Ernst S, Ferreira JC, Francey LJ, Gehlken U, Guill&#x000e9;n-Navarro E, Gyftodimou Y, Hall BD, Hennekam R, Hudgins L, Hullings M, Hunter JM, Yntema H, Innes AM, Kline AD, Krumina Z, Lee H, Leppig K, Lynch SA, Mallozzi MB, Mannini L, McKee S, Mehta SG, Micule I, Mohammed S, Moran E, Mortier GR, Moser JA, Noon SE, Nozaki N, Nunes L, Pappas JG, Penney LS, P&#x000e9;rez-Ayt&#x000e9;s A, Petersen MB, Puisac B, Revencu N, Roeder E, Saitta S, Scheuerle AE, Schindeler KL, Siu VM, Stark Z, Strom SP, Thiese H, Vater I, Willems P, Williamson K, Wilson LC, Hakonarson H, Quintero-Rivera F, Wierzba J, Musio A, Gillessen-Kaesbach G, Ramos FJ, Jackson LG, Shirahige K, Pi&#x000e9; J, Christianson DW, Krantz ID, Fitzpatrick DR, Deardorff MA, et al.  Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:2888–900.</span> [<a href="/pmc/articles/PMC4014191/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4014191</span></a>] [<a href="/pubmed/24403048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24403048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.kaname.2007.835">Kaname T, Yanagi K, Chinen Y, Makita Y, Okamoto N, Maehara H, Owan I, Kanaya F, Kubota Y, Oike Y, Yamamoto T, Kurosawa K, Fukushima Y, Bohring A, Opitz JM, Yoshiura K, Niikawa N, Naritomi K. Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:835–41.</span> [<a href="/pmc/articles/PMC2227933/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2227933</span></a>] [<a href="/pubmed/17847009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17847009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.kuechler.2017.183">Kuechler A, Czeschik JC, Graf E, Grasshoff U, H&#x000fc;ffmeier U, Busa T, Beck-Woedl S, Faivre L, Rivi&#x000e8;re JB, Bader I, Koch J, Reis A, Hehr U, Rittinger O, Sperl W, Haack TB, Wieland T, Engels H, Prokisch H, Strom TM, L&#x000fc;decke HJ, Wieczorek D. Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition. <span><span class="ref-journal">Eur J Hum Genet. </span>2017;<span class="ref-vol">25</span>:183–91.</span> [<a href="/pmc/articles/PMC5255962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5255962</span></a>] [<a href="/pubmed/27901041" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27901041</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.magini.2012.917">Magini P, Della Monica M, Uzielli ML, Mongelli P, Scarselli G, Gambineri E, Scarano G, Seri M. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations. <span><span class="ref-journal">Am J Med Genet Part A. </span>2012;<span class="ref-vol">158A</span>:917–21.</span> [<a href="/pubmed/22419483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22419483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.oberklaid.1975.1348">Oberklaid F, Danks D. The Opitz trigonocephaly syndrome. <span><span class="ref-journal">Am J Dis Child. </span>1975;<span class="ref-vol">129</span>:1348–9.</span> [<a href="/pubmed/1190170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1190170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.parenti.2016.564">Parenti I, Gervasini C, Pozojevic J, Wendt KS, Watrin E, Azzollini J, Braunholz D, Buiting K, Cereda A, Engels H, Garavelli L, Glazar R, Graffmann B, Larizza L, L&#x000fc;decke HJ, Mariani M, Masciadri M, Pi&#x000e9; J, Ramos FJ, Russo S, Selicorni A, Stefanova M, Strom TM, Werner R, Wierzba J, Zampino G, Gillessen-Kaesbach G, Wieczorek D, Kaiser FJ. Expanding the clinical spectrum of the 'HDAC8-phenotype' - implications for molecular diagnostics, counseling and risk prediction. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">89</span>:564–73.</span> [<a href="/pubmed/26671848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26671848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.pe_apadilla.2017.640">Pe&#x000f1;a-Padilla C, Marshall CR, Walker S, Scherer SW, Tavares-Mac&#x000ed;as G, Razo-Jim&#x000e9;nez G, Bobadilla-Morales L, Acosta-Fern&#x000e1;ndez E, Corona-Rivera A, Mendoza-Londono R, Corona-Rivera JR. Compound heterozygous mutations in the IFT140 gene cause Opitz trigonocephaly C syndrome in a patient with typical features of a ciliopathy. <span><span class="ref-journal">Clin Genet. </span>2017;<span class="ref-vol">91</span>:640–6.</span> [<a href="/pubmed/27874174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27874174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.russell.2013.16">Russell B, Graham JM. Expanding our knowledge of conditions associated with the ASXL gene family. <span><span class="ref-journal">Genome Med. </span>2013;2013;<span class="ref-vol">5</span>:16.</span> [<a href="/pmc/articles/PMC3706972/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3706972</span></a>] [<a href="/pubmed/23672984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23672984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.russell.2015.2122">Russell B, Johnston JJ, Biesecker LG, Kramer N, Pickart A, Rhead W, Tan W-H, Brownstein CA, Kate Clarkson L, Dobson A, Rosenberg AZ, Vergano SAS, Helm BM, Harrison RE, Graham Jr JM. Clinical management of patients with ASXL1 mutations and Bohring&#x02013;Opitz syndrome, emphasizing the need for Wilms tumor surveillance. <span><span class="ref-journal">Am J Med Genet Part A. </span>2015;<span class="ref-vol">167A</span>:2122–31.</span> [<a href="/pmc/articles/PMC4760347/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4760347</span></a>] [<a href="/pubmed/25921057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25921057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.shashi.2016.991">Shashi V, Pena LD, Kim K, Burton B, Hempel M, Schoch K, Walkiewicz M, McLaughlin HM, Cho M, Stong N, Hickey SE, Shuss CM, Freemark MS, Bellet JS, Keels MA, Bonner MJ, El-Dairi M, Butler M, Kranz PG, Stumpel CT, Klinkenberg S, Oberndorff K, Alawi M, Santer R, Petrovski S, Kuismin O, Korpi-Heikkil&#x000e4; S, Pietilainen O, Aarno P, Kurki MI, Hoischen A, Need AC, Goldstein DB, Kort&#x000fc;m F, et al.  De novo truncating variants in ASXL2 are associated with a unique and recognizable clinical phenotype. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">99</span>:991–9.</span> [<a href="/pmc/articles/PMC5065681/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5065681</span></a>] [<a href="/pubmed/27693232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27693232</span></a>]</div></li></ul></div><div id="bohring-opitz.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.addor.1995.113">Addor MC, Stefanutti D, Farron F, Meinecke P, Lacombe D, Sarlangue J, Prescia G, Schorderet DF. C Trigonocephaly syndrome with diaphragmatic hernia. <span><span class="ref-journal">Genet Counsel. </span>1995;<span class="ref-vol">6</span>:113–20.</span> [<a href="/pubmed/7546453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7546453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.antley.1981.147">Antley RM, Hwang DS, Theopold W, Gorlin RJ, Steeper T, Pitt D, Danks DM, McPherson E, Bartels H, Wiedemann HR, Opitz JM. Further delineation of the C (trigonocephaly) syndrome. <span><span class="ref-journal">Am J Med Genet. </span>1981;<span class="ref-vol">9</span>:147–63.</span> [<a href="/pubmed/7258228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7258228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.bisgaard.2007.243">Bisgaard AM, Kirchhoff M, Nielsen JE, Brandt C, Hove H, Jepsen B, Jensen T, Ullmann R, Skovby F. Transmitted cytogenetic abnormalities in patients with mental retardation: pathogenic or normal variants? <span><span class="ref-journal">Eur J Med Genet. </span>2007;<span class="ref-vol">50</span>:243–55.</span> [<a href="/pubmed/17531565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17531565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.lindor.2000.363">Lindor NM. Severe end of Opitz Trigonocephaly C Syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">92</span>:363–5.</span> [<a href="/pubmed/10861669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10861669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.mcgaughran.2000.311">McGaughran J, Aftimos S, Oei P. Trisomy of 3pter in a patient with apparent C (trigonocephaly) syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">94</span>:311–5.</span> [<a href="/pubmed/11038445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11038445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.nakane.2000.361">Nakane T, Kubota T, Fukushima Y, Hata Y, Ishii J, Komiyama A. Opitz trigonocephaly (C)-like syndrome, or Bohring-Opitz syndrome: another example. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">92</span>:361–2.</span> [<a href="/pubmed/10861668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10861668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.osaki.2006.897">Osaki M, Makita Y, Miura J, Abe N, Noguchi S, Miyamoto A. A Japanese boy with apparent Bohring-Opitz or "C-like" syndrome. <span><span class="ref-journal">Am J Med Genet Part A. </span>2006;<span class="ref-vol">140</span>:897–9.</span> [<a href="/pubmed/16528754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16528754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.pierron.2009.1754">Pierron S, Richelme C, Triolo V, Mas JC, Griffet J, Karmous-Benailly H, Quere M, Kaname T, Lambert JC, Giuliano F. Evolution of a patient with Bohring-Opitz syndrome. <span><span class="ref-journal">Am J Med Genet Part A. </span>2009;2009;<span class="ref-vol">149A</span>:1754–7.</span> [<a href="/pubmed/19606480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19606480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bohring-opitz.REF.simpson.2007.524">Simpson AR, Gibbon CE, Quinn AG, Turnpenny PD. Infantile high myopia in Bohring-Opitz syndrome. <span><span class="ref-journal">J AAPOS. </span>2007;2007;<span class="ref-vol">11</span>:524–5.</span> [<a href="/pubmed/17498985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17498985</span></a>]</div></li></ul></div></div><div id="bohring-opitz.Chapter_Notes"><h2 id="_bohring-opitz_Chapter_Notes_">Chapter Notes</h2><div id="bohring-opitz.Author_Notes"><h3>Author Notes</h3><p>Dr Bianca Russell is a clinical geneticist at Cincinnati Children's Hospital who has been studying and caring for patients with Bohring-Opitz Syndrome since meeting two patients with the condition in 2012. She met these patients while under the mentorship of Dr John Graham at Cedars Sinai Medical Center. Dr Graham has been a leader in the field of clinical dysmorphology for decades and an outstanding mentor. Dr Wen-Hann Tan is a clinical geneticist at Boston Children's Hospital who cares for several patients with BOS and was an integral part of their 2015 publication on clinical management of BOS.</p><p>Dr Russell and Dr Tan are continuing their work with the BOS community through a registry for disorders caused by pathogenic variants in the <i>ASXL</i> family of genes.</p></div><div id="bohring-opitz.Acknowledgments"><h3>Acknowledgments</h3><p>The authors would like to thank the BOS families and community for their commitment to understanding BOS and providing outstanding care for their children. They continue to be a true inspiration to the authors of this review.</p></div><div id="bohring-opitz.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 February 2018 (ma) Review posted live</div></li><li class="half_rhythm"><div>13 March 2017 (br) Initial submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK481833</span><span class="label">PMID: <a href="/pubmed/29446906" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">29446906</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bloom/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bofs/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK481833&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK481833/?report=reader">PubReader</a></li><li><a href="/books/NBK481833/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK481833" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK481833" style="display:none" title="Cite this Page"><div class="bk_tt">Russell B, Tan WH, Graham JM Jr. Bohring-Opitz Syndrome. 2018 Feb 15. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK481833/pdf/Bookshelf_NBK481833.pdf">PDF version of this page</a> (956K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#bohring-opitz.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#bohring-opitz.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#bohring-opitz.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#bohring-opitz.Genetically_Related_Alleli" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#bohring-opitz.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#bohring-opitz.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#bohring-opitz.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#bohring-opitz.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#bohring-opitz.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#bohring-opitz.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#bohring-opitz.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=171023[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ASXL1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4501308" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4501308" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4501308" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4501308" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25921057" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.</a><span class="source">[Am J Med Genet A. 2015]</span><div class="brieflinkpop offscreen_noflow">Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Russell B, Johnston JJ, Biesecker LG, Kramer N, Pickart A, Rhead W, Tan WH, Brownstein CA, Kate Clarkson L, Dobson A, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2015 Sep; 167A(9):2122-31. Epub 2015 Apr 29.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29681100" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother.</a><span class="source">[Am J Med Genet A. 2018]</span><div class="brieflinkpop offscreen_noflow">Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bedoukian E, Copenheaver D, Bale S, Deardorff M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2018 May; 176(5):1249-1252. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31692235" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Extending the phenotypic spectrum of Bohring-Opitz syndrome: Mild case confirmed by functional studies.</a><span class="source">[Am J Med Genet A. 2020]</span><div class="brieflinkpop offscreen_noflow">Extending the phenotypic spectrum of Bohring-Opitz syndrome: Mild case confirmed by functional studies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Leon E, Diaz J, Castilla-Vallmanya L, Grinberg D, Balcells S, Urreizti R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2020 Jan; 182(1):201-204. Epub 2019 Nov 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31145570" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Apert Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Apert Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wenger TL, Hing AV, Evans KN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301398" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Simpson-Golabi-Behmel Syndrome Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Simpson-Golabi-Behmel Syndrome Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sajorda BJ, Gonzalez-Gandolfi CX, Hathaway ER, Kalish JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=29446906" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=29446906" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040d1839a66ee2ba550542">Bohring-Opitz Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Bohring-Opitz Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:30:00-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE895358E040ADB10000000001040072&amp;ncbi_session=CE895358E040D171_0260SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK481833%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK481833&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK481833/&amp;ncbi_pagename=Bohring-Opitz Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE895358E040D171_0260SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>